Efficacy and safety of nail psoriasis targeted therapies: a systematic review. | 2023 | American Journal of Clinical Dermatology |
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. | 2023 | Cochrane Database of Systematic Reviews |
Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials. | 2023 | Immunologic research |
Adverse Effects of Anti-Interleukin-23 Agents Employed in Patients with Psoriasis: A Systematic Review. | 2022 | Dermatology |
Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple-treatments meta-analysis. | 2021 | Journal of the German Society of Dermatology |
Comparative efficacy and relative ranking of biologics and oral therapies for moderate-to-severe plaque psoriasis: a network meta-analysis. | 2021 | Dermatology and Therapy |
Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: a network meta-analysis of clinical trial data. | 2021 | Journal of the American Academy of Dermatology |
Therapeutic update of biologics and small molecules for scalp psoriasis: a systematic review. | 2021 | Dermatologic Therapy |
A systematic review with network meta-analysis of the available biologic therapies for psoriatic disease domains. | 2021 | Frontiers in Medicine |
Clinical review report: tildrakizumab (Ilumya). | 2021 | CADTH |
A systematic literature review and bucher indirect comparison: tildrakizumab versus guselkumab. | 2020 | Journal of Health Economics and Outcomes Research |
Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis. | 2020 | Journal of the European Academy of Dermatology and Venereology |
Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple‐treatments meta‐analysis. | 2020 | Journal of the German Society of Dermatology |
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis. | 2020 | Cochrane Database of Systematic Reviews |
Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis. | 2020 | Therapeutics and Clinical Risk Management |
Tildrakizumab for treating moderate to severe plaque psoriasis. | 2019 | NICE |
Short-term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: A systematic review and network meta-analysis of randomized controlled trials. | 2019 | Journal of Immunology Research |
Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value. | 2019 | ICER |
A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. | 2018 | The Journal of Dermatological Treatment |
Public assessment report: Ilumetri. | 2018 | EMA |